Anika Therapeutics (NASDAQ: ANIK) reported Q2 EPS of $0.17, $0.10 better than the analyst estimate of $0.07. Revenue for the quarter came in at $41.9 million versus the consensus estimate of $40.77 million.

GUIDANCE:

Anika Therapeutics sees FY2024 revenue of $168-173 million, versus the consensus of $170.8 million.

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.